The PIK3CA gene, which encodes the p110α catalytic subunit of PI3-kinase (PI3K), is mutationally activated in 26 cancer and in overgrowth disorders known as PIK3CA-related overgrowth spectrum (PROS). To determine the 27 consequences of genetic PIK3CA activation in a developmental context of relevance to both PROS and cancer, we 28 engineered isogenic human induced pluripotent stem cells (iPSCs) with heterozygous or homozygous knock-in of 29 PIK3CA H1047R . While heterozygous iPSCs remained largely similar to wild-type cells, homozygosity for 30 PIK3CA H1047R caused widespread, cancer-like transcriptional remodeling, partial loss of epithelial morphology, 31 upregulation of stemness markers and impaired differentiation to all three germ layers in vitro and in vivo. Genetic 32 analysis of PIK3CA-associated cancers revealed that 64 % had multiple oncogenic PIK3CA copies (39 %) or 33 additional PI3K signaling pathway-activating "hits" (25 %). This contrasts with the prevailing view that PIK3CA 34 mutations occur heterozygously in cancer. Our findings suggest that a PI3K activity threshold determines 35 pathological consequences of oncogenic PIK3CA activation and provide the first insight into the specific role of this 36 pathway in human pluripotent stem cells. 37 38
4 expression of the pluripotency factors Nanog and Pou5f1 (Oct3/4) (22) . Despite the insights gained from these and 79 other mouse models of oncogenic PIK3CA, efforts to establish in vivo models of PROS have highlighted that species 80 differences may constrain extrapolation from model organisms to the mechanisms of pathological PI3K activation 81 in human disease (5).
82
Due to their unlimited self-renewal and differentiation capacity, human pluripotent stem cells are 83 increasingly used as tools to develop more relevant human disease models (23) . Their inherent similarities to cancer 84 cells also make them an attractive system in which to study oncogenic processes (24) . Thus, to study dose-dependent 85 effects of pathological PI3K hyperactivation in a developmental system of relevance to cancer and PROS, we 86 engineered isogenic human induced pluripotent stem cells (iPSCs) to express PIK3CA H1047R from one or both 87 endogenous loci. Our data reveal clear dose-dependent developmental phenotypes downstream of p110a activation, 88 with homozygosity but not heterozygosity for PIK3CA H1047R promoting self-sustained stemness in vitro and in vivo.
89
These findings emphasize the importance of using precisely-engineered models of cancer-associated PIK3CA 90 variants to obtain a faithful representation of their biological effects and have implications for our understanding of 91 PI3K activation in human disease.
93

Results
94
Generation of human iPSCs with endogenous expression of PIK3CA H1047R
95
To establish a cell model suitable for interrogation of allele dose-dependent consequences of p110a 96 activation in human development and disease, we used CRISPR/Cas9 genome editing of well-characterized, 97 karyotypically normal wild-type (WT) iPSCs to generate multiple isogenic clones either heterozygous (n = 3) or 98 homozygous (n = 10) for the activating PIK3CA H1047R allele (Figure 1a,b, Figure S1a ). To control for non-specific 99 effects caused by genetic drift following so-called bottleneck selection (25, 26), we expanded six WT clones exposed 100 to the gene targeting process. Sequencing of multiple clones of each genotype showed no evidence of mutagenesis 101 of 17 computationally predicted CRISPR off-target sites (Figure S1b) , and a normal karyotype was confirmed in 102 three homozygous and two heterozygous clones more than 10 passages after targeting (Figure S1c ), suggesting that 6 was progressively enhanced across heterozygous and homozygous mutant cells (Figure 2d) . These findings suggest 136 that the MAPK/ERK pathway is primed to hyper-respond to growth factor stimulation in PIK3CA H1047R stem cells, 137 in an allele dose-dependent manner.
139
Transcriptomic effects of PIK3CA H1047R in pluripotent stem cells
140
To determine the wider dose-dependent consequences of genetic p110α activation, we profiled the protein-141 coding transcriptome of WT, PIK3CA WT/H1047R and PIK3CA H1047R/H1047R iPSCs, cultured in growth factor-replete 142 conditions to mimic the in vivo milieu of the pluripotent epiblast. Multidimensional scaling demonstrated distinct 143 transcriptomic signatures of WT, heterozygous and homozygous cells (Figure 3a) . The transcriptome of 144 PIK3CA WT/H1047R cells was nearly identical to WT controls, with only 131 differentially-expressed transcripts (FDR 145 = 0.05). In contrast, homozygosity for PIK3CA H1047R led to differential expression of 1,914 genes (Figure 3a) . This 146 indicates widespread transcriptional remodeling with a sharp allele dose-dependency, suggestive of a threshold 147 effect.
148
KEGG annotation-based pathway analysis using all 1,914 differentially-expressed genes in 149 PIK3CA H1047R/H1047R cells demonstrated significant changes to PI3K/AKT signaling, as expected. "Pathways in 150 cancer" was identified as a common central node, demonstrating the power of our isolated genetic activation of PI3K 151 to recapitulate signatures identified in the genetically far more chaotic context of tumors (Figure 3b) . Other pathways 152 identified as showing coherent perturbations were "Extracellular matrix-receptor interaction" and "Focal adhesion", 153 in keeping with the altered morphology and adhesion properties of homozygous mutants. Several genes involved in 154 pluripotency regulation and WNT signaling were also differentially expressed. Finally, the TP53 pathway was found 155 to be significantly altered (Figure 3b) . This is consistent with prior evidence of TP53 activation in cell lines with 156 hyperactivation of PI3K/AKT (29-32), however given the recent report that a substantial proportion of iPSC lines 157 have TP53 mutations (33), we sequenced the TP53 gene of all clones. We found that two of the WT lines were 158 indeed heterozygous for TP53 C135F (Figure S3a) , a mild loss-of-function allele based on biochemical assays in 159 yeast (34). Despite this, inspection of each iPSC clone's RNAseq data for the differentially expressed TP53 signaling 160 genes showed that the signature difference in PIK3CA H1047R/H1047R cells was not attributable to these two WT lines.
161
To identify potential drivers of the transcriptional changes in PIK3CA H1047R/H1047R cells, we also undertook 162 Ingenuity ® Pathway Analysis of upstream regulators. This again revealed the expected activation of PI3K/AKT 163 signaling. It also implicated factors important in stem cell regulation, including TGFβ, FGF2, TP53, β-catenin and 164 7 MYC (Figure 3c) . TGFβ was the most significant prediction, and supporting increased signaling within this 165 pathway, we found increased phosphorylation of SMAD2 in homozygous mutants (Figure S3b) . These cells also 166 had upregulated expression of NODAL (Figure 3b, d) , a member of the TGFβ superfamily that maintains the 167 pluripotent epiblast at early developmental stages and later induces primitive streak formation during gastrulation 168 (35) . Consistent with NODAL's dual function, PIK3CA H1047R/H1047R cells exhibited a stemness signature (36) 169 including upregulation of NANOG, POU5F1 (OCT3/4), MYC, KDR, IGF1R, as well as upregulation of primitive 170 streak markers such as FGF4, GDF3 and FOXA2 (Figure 3b, d) . Upregulation of NODAL in WT and mutant cells 171 was abolished by p110a-specific inhibition with BYL719 ( Figure S3c) . In comparison, NANOG expression 172 remained mostly unaffected by BYL719, with a trend towards downregulation after 48 h of p110a inhibition 173 ( Figure S3c) . These findings suggest upregulation of NODAL and enhanced TGFb/SMAD2 signaling as a 174 candidate mechanism whereby p110a activation may exert effects on stemness in human pluripotent stem cells.
176
Homozygosity for PIK3CA H1047R confers self-sustained stemness upon embryoid bodies 177 Embryoid bodies (EBs) are widely used to model lineage specification during gastrulation (37, 38).
178
Previous studies have shown that NODAL overexpression in human pluripotent stem cell-derived EBs blocks 179 differentiation to all three germ layers (39). Given the evidence for upregulated NODAL and TGFβ signaling in 180 PIK3CA H1047R/H1047R cells, we tested whether the resulting EBs would behave similarly to NODAL-overexpressing 181 EBs. EBs were established without TGFβ and FGF2, cultured in suspension for four days and allowed to generate 182 adherent outgrowths for six days (Figure 4a ). PIK3CA H1047R/H1047R stem cells consistently generated compact, cystic 183 EBs that failed to bud and undergo internal reorganization (Figure 4b) , with notable resemblance to mouse EBs 184 overexpressing constitutively-active PDK1 or AKT1 (40). In adherent culture, PIK3CA H1047R/H1047R EB outgrowths 185 resembled stem cell colonies (Figure 4b ). Confirming this, PIK3CA H1047R/H1047R EB outgrowths stained positive for 186 the stemness markers OCT3/4, NANOG and TRA-1-60 (Figure 4c ). WT and PIK3CA WT/H1047R EBs, in contrast, 187 exhibited complex morphologies in suspension and yielded heterogeneous outgrowths of differentiated cells which 188 continued to mature during the experiment (Figure 4b,c ).
189
The apparent differentiation block of PIK3CA H1047R/H1047R EBs was assessed transcriptionally using lineage-190 specific arrays and candidate gene quantitative PCR. Unlike WT and PIK3CA WT/H1047R EBs, homozygous mutants 191 exhibited sustained expression of stemness genes and failed to upregulate germ layer-specific markers, both in 192 8 adherent cultures and in suspension (Figure 4d, Figure S4a-d) . This phenotype persisted in the presence of serum, 193 which is used to induce EB differentiation (Figure 4d, Figure S4a ). Attempts to reverse the PIK3CA H1047R/H1047R EB 194 phenotype with the p110a inhibitor BYL719 were unsuccessful due to poor EB survival in the presence of the drug, 195 consistent with previous studies demonstrating high EB sensitivity to PI3K/mTOR inhibition (40-42).
197
Heterozygosity for PIK3CA H1047R is compatible with directed definitive endoderm formation 198 Heterozygosity for PIK3CA H1047R did not produce major perturbations in the transcriptome of iPSCs nor in 199 EB differentiation. Nevertheless, observation of PIK3CA-driven overgrowth in PROS suggests that mesodermal 200 and neuroectodermal tissues are widely involved while tissues of endodermal origin are only rarely affected by 201 strong activating mutations, raising the possibility of negative selection during endodermal development (5). We 202 thus sought to undertake more systematic analysis of early differentiation in our human developmental models of 203 PIK3CA H1047R . To overcome the high variability seen in self-aggregating, spontaneously-differentiating EBs, the 204 protocol was modified (Figure 5a) , incorporating use of microwell plates to ensure homogeneous EB size. EB 205 formation was followed by three days of exposure to different concentrations of Activin A, BMP4 and FGF2 to 206 promote mesoderm or definitive endoderm formation (43, 44) . Lineage-specific gene expression arrays, candidate 207 gene quantitative PCR and immunostaining assays were used to assess expression of multiple differentiation markers 208 (Figure 5b,c) . Mesoderm or endoderm induction led to increased expression of the expected lineage-specific 209 markers (Figure 5b, Figure S5 ). The temporal pattern and relative expression levels of the analyzed genes was 210 similar for PIK3CA WT/H1047R and WT EBs (Figure 5b, Figure S5 ), and adherent outgrowths from both stained 211 positive for mesoderm and endoderm markers at the end of the 10-day protocol (Figure 5c ). The results of this assay 212 argue against an inability of PIK3CA WT/H1047R iPSCs to yield definitive endoderm.
213
We also subjected WT and PIK3CA H1047R -harbouring cell lines to monolayer-based directed differentiation 214 using a combination of low serum, inhibition of GSK3 and high levels of Activin A (45) (Figure 6a) . The 215 differentiation medium was also supplemented with DMSO (control) or BYL719 (100 nM), in anticipation that high 216 PI3K signaling would be incompatible with two-dimensional definitive endoderm formation, as reported previously 217 (46, 47) . Unexpectedly, both PIK3CA WT/H1047R and PIK3CA H1047R/H1047R iPSCs differentiated successfully to definitive 218 endoderm under these directed conditions, as evidenced by gene expression analysis and immunostaining ( Figure   219 6b,c). The dynamics of gene expression were closely similar across the three genotypes and were unaffected by 220 p110α inhibition (Figure 6b ). Confirming that this was not a donor-specific effect, similar results were obtained with 221 9 isogenic WT and mutant iPSCs derived from a PROS patient with mosaic, heterozygous expression of the rare 222 PIK3CA E418K allele (Figure S6) . These findings suggest that PI3K activation is compatible with definitive endoderm 223 formation in vitro, contrary to previous conclusions based on the use of non-specific pan-PI3K inhibitors with known 224 off-target effects (46, 47), and do not support cell-autonomous negative selection in early lineage specification in 225 PROS.
227
Allele dose-dependent effects of PIK3CA H1047R in vivo
228
To confirm that allele dose-dependent effects of PIK3CA H1047R were not artefacts of in vitro culture, we 229 injected immunodeficient mice with WT or mutant iPSCs, and allowed them to form tumors over 5-8 weeks before 230 histopathological assessment. WT and PIK3CA WT/H1047R tumors contained differentiated components of the three 231 germ layers, including bone, cartilage, pigmented epithelium, nervous tissue and tubular endodermal structures 232 (Figure 7a , Table S1 ). All PIK3CA WT/H1047R tumors exhibited better differentiated endoderm-derived tissues 233 including respiratory (all lines) and gastrointestinal (one line) epithelium, corroborating the in vitro finding that 234 heterozygosity for PIK3CA H1047R does not impair definitive endoderm formation. In contrast, differentiated 235 components were either completely absent or very immature in the two PIK3CA H1047R/H1047R tumors (Figure 7a, 
236
Table S1), consistent with the inability of the parental cells to yield spontaneously-differentiated EBs. The least 237 mature of the PIK3CA H1047R/H1047R tumors showed extensive recruitment of mouse stromal cells, forming septae 238 separating lobules of immature human tissue ( Figure S7a ). Homozygous tumors also exhibited extensive necrosis 239 and yolk sac-like tissue formation (Figure 7a) , the latter suggested to be an in vivo characteristic of injected 240 pluripotent stem cells with malignant potential (48). They also contained multiple foci positive for T BRACHYURY 241 (immature mesoderm) and nuclear OCT3/4 (embryonal carcinoma marker in germ cell tumors) (Figure S7c,d) .
242
These results are in line with the in vitro studies and demonstrate that homozygosity but not heterozygosity 243 for PIK3CA H1047R promotes stemness of human pluripotent stem cells. Stem cells share many similarities with cancer 244 cells, and phenotypes such as dedifferentiation and reactivation of developmental pathways have been linked to 245 epithelial-to-mesenchymal transition and aggressive tumor behavior in vivo (49). PIK3CA mutations in human 246 tumors are not mutually-exclusive with other oncogenic alterations promoting PI3K pathway activation, suggesting 247 that further activation is positively selected for (50). This raises the possibility that our findings may be relevant to 248 understanding the behavior of human cancer. We thus analyzed the prevalence of multiple oncogenic "hits" within 249 the PI3K pathway using data from The Cancer Genome Atlas on cancer types with >10% prevalence of PIK3CA 250 10 mutations. In aggregate, 21% of these cancers had PIK3CA mutations. Nearly 40% of this subset had more than one 251 copy of the mutation, and 25% also had a mutation in other selected PI3K pathway components (PTEN, PIK3R1, 252 AKT1/2/3), or harbored a second PIK3CA variant (Figure 7b) . This high frequency of additional mechanisms 253 activating PI3K signaling in cancers provides circumstantial support for the notion that the strength of PI3K 254 hyperactivation may be important for tumor progression in vivo.
256
Discussion
257
We present the first pluripotent stem cell model permitting assessment of the consequences of selective 258 genetic p110α activation specifically in a human developmental context. This is important given the well-259 documented differences between the pathways regulating mouse and human stem cell pluripotency and 260 differentiation (51). By using CRISPR-mediated knock-in of PIK3CA H1047R into one or both endogenous PIK3CA 261 alleles, we were able to examine the importance of mutant PIK3CA allele dosage for pathway activation and 262 downstream cellular responses. Human pluripotent stem cells are useful not only for study of human embryogenesis 263 but also of the effects of pathological PI3K signaling, as seen in PROS and cancer cells (52). The model we have 264 generated may thus be useful for understanding oncogenic actions of PIK3CA H1047R in different contexts. By using 265 expression from endogenous loci, by studying multiple clones of each genotype, and by controlling for non-specific 266 variation introduced during the targeting process, we have minimized analytic problems arising from overexpression 267 of the gene of interest and from non-specific genetic and chromosomal abnormalities.
268
PIK3CA H1047R increased PI3K signaling "tone" both in growth factor-replete and growth factor-depleted 269 medium. Most strikingly, we report distinct allele dose-dependent effects of mutant PIK3CA on stemness and 270 pluripotency in vitro and in vivo, with a corresponding major alteration of the transcriptome triggered at a threshold 271 between heterozygous and homozygous p110a activation. At odds with our finding in human stem cells, 272 heterozygous expression of PIK3CA H1047R in a human MCF10A breast epithelial cell line has previously been shown 273 to cause widespread transcriptional changes, illustrating the notion that small changes in a non-linear system can 274 have extensive consequences (53, 54). However, the mutant cells in these studies also had amplification of 275 chromosome 5p13-15 (54), a region harboring the gene encoding the catalytic subunit of telomerase. This could 276 have contributed to the observed discrepancy to our study. Alternatively, thresholds at which p110a signaling 277 triggers its transcriptional effects may differ among cell types. Exemplifying this, either overexpression or 278 11 endogenous expression of PIK3CA H1047R induces multipotency in mammary tumors (8, 16) , with the tumor cell of 279 origin dictating phenotypic severity.
280
Although we describe the first stem cell-based study focusing on endogenous expression of the commonest 281 pathogenic PIK3CA allele, several other studies have adopted different strategies to activate other components of the 282 PI3K/AKT signaling cascade in this cell type (40, (55) (56) (57) (58) . Self-sustained stemness is a common motif in the 283 phenotypes reported, and some studies, like ours, argue for discernible PI3K dose-dependency. For example, mouse 284 pluripotent stem cells with homozygous knockout of the non-specific type IA PI3K negative regulator Pten exhibit 285 impaired differentiation in vitro and in vivo, but this is not seen in heterozygous knockout cells (57). How strong 286 PI3K activation sustains stemness remains to be determined, however our data suggest that induction of 287 TGFβ/NODAL signaling is likely to be important. Supporting this, several transcriptional changes observed in 288 PIK3CA H1047R/H1047R cells were reciprocal to those in human pluripotent stem cells exposed to pharmacological 289 inhibition of TGFβ signaling (59). It is also possible that the direct link between PI3K activation and NODAL 290 expression underlies the previously reported association between PI3K/AKT activation and expression of NANOG 291 (56, 60), a key pluripotency gene controlled by SMAD2/3 (61).
292
Our report of marked allele dose-dependent effects of PIK3CA H1047R may have implications for 293 understanding of PI3K-associated cancers. Many human cancers feature oncogenic alterations in PIK3CA, and not 294 only are these frequently present in more than one copy, but they are also frequently accompanied by mutations of 295 other pathway components, suggesting that cancer cells benefit from additional PI3K pathway activation. Future 296 studies of the role of the PI3K pathway in cancer progression should incorporate consideration of PI3K signaling 297 "dose" and the possibility of clear thresholds for biological consequences. Such considerations echo recent reports 298 that an increased dosage of mutant KRAS influences clinical outcome and therapeutic targeting (62, 63). Based on 299 our observations in human pluripotent stem cells with homozygosity for PIK3CA H1047R , it will be interesting to 300 determine whether cancers with stronger activation of PI3K exhibit more aggressive features such as a higher degree 301 of dedifferentiation and metastatic potential.
302
In contrast to the complex genetics of cancer, activating PIK3CA mutations arise heterozygously and in 303 isolation in the severe overgrowth disorders known as PROS. An excess risk of adult cancer has not been reported 304 in these mosaic disorders, in line with the notion that heterozygosity for PIK3CA H1047R alone is not sufficient to cause 305 cellular transformation. PROS also illustrates the importance of control of p110α signaling in early human 306 development. Overgrowth in PROS commonly affects mesodermal and neuroectodermal lineages but rarely 307 12 endoderm-derived tissues, prompting speculation that a sustained increase in PI3K activation impairs endoderm 308 development (5). It has also been reported that class IA PI3K signaling is incompatible with directed definitive 309 endoderm formation from human pluripotent stem cells, although this assertion is largely based on use of non-310 specific pan-PI3K inhibitors (46, 47) . In our study, we found no evidence that genetic PI3K activation impairs guided 311 definitive endoderm formation in culture. Moreover, PIK3CA WT/H1047R pluripotent stem cells gave rise to teratomas 312 featuring well-differentiated endodermal components, arguing against a cell-autonomous defect in endoderm 313 specification as an explanation for overall lack of endodermal overgrowth in PROS. The relatively mild biochemical 314 and transcriptional consequences of heterozygous PIK3CA activation in stem cells, and their grossly normal early 315 differentiation in several different experimental contexts suggests that any negative selection in certain lineages may 316 be exerted only at later stages of differentiation. In contrast, homozygosity for PIK3CA H1047R in early development 317 will likely be selected against due to impaired differentiation.
318
In summary, this study demonstrates that the cellular consequences of the most common oncogenic 319 PIK3CA mutation are allele dose-dependent. The observed near binary differences between PIK3CA H1047R 320 heterozygosity and homozygosity suggest that cells may have a PI3K signaling threshold that determines the Table S1 . b. The Cancer Genome Atlas was used to extract genomic data from PIK3CA-associated cancers. These 620 were analyzed in aggregate for the presence or absence of mutant PIK3CA alleles, followed by stratification of 621 PIK3CA mutant-positive samples based on the presence of multiple mutant alleles, including cases where the wild-622 type (WT) PIK3CA allele is lost (WT-). Alternatively, PIK3CA mutant-positive samples were screened for multiple 623 distinct PIK3CA mutations (*) or for the presence of additional mutations in proximal PI3K pathway components. 
